MetaCap

Mentari Therapeutics (MTRI) vs Syndax Pharmaceuticals (SNDX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Mentari Therapeutics is the larger company by market cap ($856.9 million vs $785.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MTRI+0.68%SNDX-55.87%
+41%-10%-61%
Aug 17, 20261 yearNov 20, 2026
MTRI+0.68%SNDX-55.62%
+32%-14%-60%
Aug 17, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MTRI versus SNDX key metrics
MetricMTRISNDX
Share price$14.70$8.72
Market cap$856.94M$785.05M
1-day change-3.57%-4.49%
YTD return—-58.50%
1-year return—-50.00%
5-year return—-47.09%
EPS (TTM)—$-2.37
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$172.35M
Revenue growth (YoY)—+627.84%
Net income (latest FY)—$-285.42M
Operating margin—-158.45%
Net margin—-165.60%
52-week high$23.30$25.59
52-week low$5.75$8.41
Distance from 52-week high-36.91%-65.92%
Analyst consensusstrong_buystrong_buy
Avg. price target upside—+306.54%
Average volume19.42K2.63M
Shares outstanding58.30M90.03M
Employees—298
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Mentari Therapeutics

MTRI stock →

Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways.

Health Care · Biotechnology: Pharmaceutical Preparations

About Syndax Pharmaceuticals

SNDX stock →

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees

MTRI vs SNDX FAQ

Which is bigger, Mentari Therapeutics or Syndax Pharmaceuticals?

Mentari Therapeutics (MTRI) is larger, with a market capitalization of $856.94M compared with $785.05M for Syndax Pharmaceuticals (SNDX).

Are Mentari Therapeutics and Syndax Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons